The frequency of metabolically healthy and unhealthy phenotypes in women aged 25–44 years with different levels of thyroid-stimulating hormone, prolactin, leptin

Reports that the risk of developing cardiovascular diseases in obesity is not the same, led to the allocation of metabolically healthy and unhealthy phenotypes (MHP and MUHP), this concept is based on the ability of adipose tissue to produce a number of adipokines, one of which is leptin. Hormones such as thyroid-stimulating hormone (TSH) and prolactin (PRL) are interesting from the point of view of their effect on metabolism. Aim of the study was to investigate the prevalence of MHP and MUHP in young women with different body mass index (BMI) and hormonal status (TSH, PRL, leptin) in different phenotypes. Material and methods. A group of women (n = 655) was selected from a representative sample of the Novosibirsk population aged 25–44 to study clinical and laboratory parameters. The design is a cross – sectional, observational, single – centre study. IDF, 2005 and NCEP ATP III, 2001 criteria were used to evaluate the MHP and MUHP. Results and discussion. The prevalence of MUHP in young women in Novosibirsk was 22.3 %, MHP – 77.7 % according to IDF, 2005; according to NCEP ATP III, 2001 – 13.1 and 86.9 %, respectively. The prevalence of MUHP increased with increasing BMI from 4.0 to 72.0 % according to IDF, 2005 and from 2.3 to 58.0 % according to NCEP ATP III, 2001, respectively. In obese women, MUHP was detected twice as often as MHP – 72 and 28 % according to IDF, 2005, 58 and 42 % according to NCEP ATP III, 2001. TSH and PRL do not provide information about metabolic health in young women. Leptin content is associated with BMI. The threshold value of the leptin level was 18.3 ng/ml with maximum sensitivity and specificity (Se = 53.3 %, Sp = 81.5 %), 14.5 ng/ml with equal sensitivity and specificity (Se = 65.7 %, Sp = 65.7 %). The area under ROC curve (AUC) for diagnosis of MUHP was 0.727 (SE = 0.029, p < 0.0001). Conclusion. The frequency of MHP in young women decreases with increasing BMI. MUHP is 3.5 times less common than MHP according to IDF criteria, 2005. TSH and PRL are not associated with the metabolic phenotype in young women. A leptin level more than 18.3 ng/ml has been identified as one of the markers for the recognition of MUHP in women aged 25–44 years, regardless of BMI.

1. Drapkina O.M., Eliashevich S.O., Shepel R.N. Obesity as a risk factor for chronic non-communicable diseases. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2016;(6):73–79. [In Russian]. doi: 10.15829/1560-4071-2016-6-73-79

2. Sims E.A. Are there persons who are obese, but metabolically healthy? Metabolism. 2001;50(12):1499–1504. doi: 10.1053/meta.2001.27213

3. Karelis A.D., Brochu M., Rabasa-Lhoret R., Garrel D., Poehlman E.T. Clinical markers for the identification of metabolically healthy but obese individuals. Diabetes Obes. Metab. 2004;6(6):456–457. doi: 10.1111/j.1462-8902.2004.00377.x

4. Mustafina S.V., Shcherbakova L.V., Kozupeeva D.A., Malyutina S.K., Ragino Yu.I., Rymar O.D. Тhe prevalence of metabolically healthy obesity: data from the epidemiological survey in of Novosibirsk. Ozhireniye i metabolism = Obesity and Metabolism. 2018;15(4):31–37. [In Russian]. doi:10.14341/omet9615

5. Phillips C.M. Metabolically healthy obesity across the life course: epidemiology, determinants, and implications. Ann. NY Acad. Sci. 2017;1391(1):85–100. doi: 10.1111/nyas.13230

6. Kosygina A.V. Adipocytokines in scientific and clinical practice. Ozhireniye i metabolism = Obesity and Metabolism. 2011;8(1):32–39. [In Russian]. doi: 10.14341/2071-8713-5189

7. Chan J.L., Heist K., DePaoli A.M., Veldhuis J.D., Mantzoros C.S. The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. J. Clin. Invest. 2003;111:1409–1421. doi: 10.1172/JCI17490

8. Farr O.M., Gavrieli A., Mantzoros C.S. Leptin applications in 2015: what have we learned about leptin and obesity? Curr. Opin. Endocrinol. Diabetes Obes. 2015;22(5):353–359. doi: 10.1097/MED.0000000000000184

9. Jamar G., Caranti D.A., de Cassia Cesar H., Masquio D.C.L., Bandoni D.H., Pisani L.P. Leptin as a cardiovascular risk marker in metabolically healthy obese: Hyperleptinemia in metabolically healthy obese. Appetite. 2017;108:477–482. doi: 10.1016/j.appet.2016.11.013

10. Farkhondeh T., Llorens S., Pourbagher-Shahri A.M., Ashrafizadeh M., Talebi M., Shakibaei M., Samarghandian S. An overview of the role of adipokines in cardiometabolic diseases. Molecules. 2020;25(21):5218. doi: 10.3390/molecules25215218

11. Teixeira P.F.D.S., dos Santos P.B., Pazos-Moura C.C. The role of thyroid hormone in metabolism and metabolic syndrome. Ther. Adv. Endocrinol. Metab. 2020;11:2042018820917869. doi: 10.1177/2042018820917869

12. Ruyatkina L.A., Ruyatkin D.S. Subclinical hypothyroidism and metabolic syndrome: reasons for drug intervention. Ozhireniye i metabolism = Obesity and Metabolism. 2020;17(1):41–47. [In Russian]. doi: 10.14341/omet12282

13. Voevoda S.M., Shcherbakova L.V., Denisova D.V., Shakhtshneyder E.V., Ragino Yu.I., Stakhneva E.M., Rymar O.D. Association of atherosclerosisassociated cardiovascular risk factors at different levels of prolactin in women of reproductive age. Ateroskleroz = Atherosclerosis. 2018;14(4):67–72. [In Russian]. doi: 10.15372/ATER20180407

14. Levin A., Stevens P.E. Summary of KDIGO 2012 CKD Guideline: Behind the scenes, need forguidance, and a framework for moving forward. Kidney Int. 2014;85:49–61. doi: 10.1038/ki.2013.444

15. Mamedov M.N. International diabetes federation consensus on definition of the metabolic syndrome: facts and comments. Ratsional’naya farmakoterapiya v kardiologii = Rational Pharmacotherapy in Cardiology. 2009;5(6):47–50. [In Russian]. doi: 10.20996/1819-6446-2009-5-6-47-50

16. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497. doi: 10.1001/jama.285.19.2486

17. Ostrovskaya E.V., Romantsova T.I., Gerasimov A.N., Novoselova T.E. The prevalence of metabolically healthy obesity according to the sample of the Moscow region. Ozhireniye i metabolism = Obesity and Metabolism. 2017;14(4):51–56. [In Russian]. doi: 10.14341/OMET2017451-56

18. Mustafina S.V., Vinter D.A., Shcherbakova L.V., Malyutina S.K., Ragino Yu.I., Rymar O.D. The genderspecific features prevalence of the metabolic healthy obesity phenotype. Byulleten’ sibirskoy meditsiny = Bulletin of Siberian Medicine. 2020;19(1):76–84. [In Russian]. doi: 10.20538/1682-0363-2020-1-76–84

19. Echouffo-Tcheugui J.B., Short M.I., Xanthakis V., Field P., Sponholtz T.R., Larson M.G., Vasan R.S. Natural history of obesity subphenotypes: dynamic changes over two decades and prognosis in the framingham heart study. J. Clin. Endocrinol. Metab. 2019;104(3):738–752. doi: 10.1210/jc.2018-01321

20. van Vliet-Ostaptchouk J.V., Nuotio M.L., Slagter S.N., Doiron D., Fischer K., Foco L., Gaye A.,Gögele M., Heier M., Hiekkalinna T., … Wolffenbuttel B.H.. The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. BMC Endocr. Disord. 2014;14:9. doi: 10.1186/1472-6823-14-9

21. Boyarinova M.A., Rotar O.P., Erina A.M., Paskar N.A., Alieva A.S., Moguchaia E.V., Kolesova E.P., Konradi A.O. Metabolically healthy obesity: predictors of transformation to unhealthy phenotype in St Petersburg population (according to the ESSERF study). Arterial’naya gipertenziya = Arterial Hypertension. 2021;27(3):279–290. [In Russian]. doi: 10.18705/1607-419X-2021-27-3-279-290

22. Chulkov V.S., Sinitskiy A.I., Vereina N.K., Gavrilova E.S., Chulkov Vl.S., Martynov S.A., Tkachenko P.E. Factors of cardiometabolic risk in various phenotypes of obesity in the young. Sovremennye problemy nauki i obrazovaniya = Modern Problems of Science and Education. 2020;6:181. [In Russian]. doi: 10.17513/spno.30438

23. Gijón-Conde T., Graciani A., Guallar-Castillón P., Aguilera M.T., Rodríguez-Artalejo F., Banegas J.R. Leptin Reference values and cutoffs for identifying cardiometabolic abnormalities in the spanish population. Rev. Esp. Cardiol. (Engl. Ed.). 2015;68(8):672–679. doi: 10.1016/j.rec.2014.08.015

24. Romantsova T.I., Ostrovskaya E.V. Metabolically healthy obesity: definitions, protective factors, clinical relevance. Al’manakh klinicheskoy meditsiny = Almanac of Clinical Medicine. 2015;S1:75–87. [In Russian]. doi: 10.18786/2072-0505-2015-1-75-86